Ethics committees and funding agencies often receive protocols that involve either too many or too few animals to answer the specific research question being investigated. It is evident that a greater ...

FY25 profit surge, discounted valuation, and ReSPECT Phase III Rezzayo catalyst in Q2 2026. Click for this CRMD update.

Ten years after tailored radiotherapy (RT) for breast cancer, fewer than 3% of patients had locoregional recurrences (LRR), ...

There is a lack of studies on lifestyle interventions to improve asthma and allergic disease in women, and Sharmilee M.

A 2026 product overview examining Trimology's RS2 resistant starch formulation, probiotic ingredient research, BioSignal ...

Good morning, everyone, and welcome to Imunon's Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call. During to ...

An evolving understanding of the risks and benefits of HRT has led to a reevaluation of the role of HRT for breast cancer survivors.

A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses ...

Phase II Study in Fragile X Syndrome -- IND clearance received from FDA; first patient enrollment targeted by year-end with ...

A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.